A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Inclusion Criteria:

• Has voluntarily agreed to participate in this clinical trial.
• Adults over 19 years of age
• Diagnosed with type 2 diabetes

Exclusion Criteria:

• Has severe renal and liver disorders
• Has type 1 diabetes
• Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study
• Those who are deemed ineligible to participate in the study by the investigator